STOCK TITAN

TNL Mediagene WTS (TNMWF) Stock Price, News & Analysis

TNMWF OTC
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
11 25 sessions, November 13, 2025 to November 11, 2026
Largest daily move
+450% close of May 6, 2026

Company Description

TNL Mediagene WTS (TNMWF) represents warrants related to TNL Mediagene, a foreign private issuer that reports to the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934. The underlying company, TNL Mediagene, files reports on Form 20-F and Form 6-K as a non-U.S. issuer. These filings provide information about its capital structure, corporate actions and material agreements that are relevant for holders of its ordinary shares and related securities such as warrants.

TNL Mediagene is identified in SEC filings as having corporate locations in Tokyo, Japan and Taipei City, Taiwan. As a foreign issuer, it uses Form 6-K to furnish current reports about significant events and agreements. For investors researching TNMWF, these disclosures help explain developments that may affect the warrants and the underlying ordinary shares.

Corporate and regulatory context

According to its SEC reports, TNL Mediagene is a foreign private issuer that indicates it files annual reports on Form 20-F. It also furnishes Form 6-K current reports for specific corporate events. These documents can include press releases, shareholder letters and descriptions of material contracts. The warrant symbol TNMWF is tied to the equity of TNL Mediagene, and information about the company’s share purchase arrangements and other financing activities can be relevant when evaluating the warrants.

In one Form 6-K, TNL Mediagene describes an ordinary share purchase agreement with Tumim Stone Capital LLC, referred to as an equity line of credit. An amendment to this agreement revises the valuation method for Tumim’s purchases of TNL Mediagene’s ordinary shares, allowing the company to select a pricing valuation period of one or three trading days based on market price and/or trading volume. The amendment also adjusts the maximum purchase amount and purchase price for Tumim’s purchases under the agreement. The full text of this amendment is filed as an exhibit to the Form 6-K.

Key disclosures for TNMWF investors

For those analyzing TNMWF, the most relevant information in TNL Mediagene’s SEC filings includes:

  • Its status as a foreign private issuer reporting under the Securities Exchange Act of 1934.
  • Use of Form 20-F for annual reporting and Form 6-K for current reports.
  • Details of the ordinary share purchase agreement with Tumim Stone Capital LLC and subsequent amendments.
  • Press releases and shareholder letters furnished as exhibits to Form 6-K filings.

These disclosures help explain how TNL Mediagene may raise capital through equity arrangements and how the pricing and volume of ordinary share purchases are determined. Because TNMWF is a warrant linked to TNL Mediagene’s equity, such capital-related agreements can be important for understanding potential dilution, trading dynamics and other factors that may influence the warrants.

Use of Form 6-K and exhibits

TNL Mediagene’s Form 6-K filings reference exhibits such as press releases, shareholder letters and the full text of amendments to agreements. For example, one filing lists a press release and shareholder letter dated in mid-September, and another lists a third amendment to the ordinary share purchase agreement with Tumim Stone Capital LLC as an exhibit. These exhibits are incorporated by reference into the filings and provide additional narrative and contractual detail beyond the summary descriptions in the body of the Form 6-K.

Investors and researchers can use these filings to better understand TNL Mediagene’s financing arrangements and communications with shareholders. While the warrant symbol TNMWF itself is not described in detail in the provided filings, its value is linked to the underlying ordinary shares of TNL Mediagene, making the company’s SEC disclosures a key source of information.

Stock Performance

$0.0013
No recent trading
Last close: November 11, 2026
-
1 year to November 11, 2026

TNL Mediagene WTS (TNMWF) closed at $0.0013 on November 11, 2026.

See what a $1,000 investment in TNMWF was worth at its last close

TNMWF Metrics & Rankings

Price returns through November 11, 2026. Ranking links may use different dates.

Latest News

No recent news available for TNMWF.

Financial Highlights

TNL Mediagene WTS generated $45.0M in revenue in FY2025, retaining a 31.1% gross margin, operating income reached -$49.6M, and net income was -$44.6M, reflecting a -99.0% net profit margin. Diluted earnings per share stood at -$25.91. The company generated -$4.9M in operating cash flow. The current ratio was 0.50, measuring current assets divided by current liabilities.

$45.0M
Revenue (FY2025)
-$44.6M
Net Income (FY2025)
-$4.9M
Operating Cash Flow

Upcoming Events

No upcoming events scheduled for TNMWF.

Short Interest History

Last 12 Months

Short interest in TNL Mediagene WTS (TNMWF) currently stands at 493 shares, representing 0.0% of the shares outstanding.

Days to Cover History

Last 12 Months

Days to cover for TNL Mediagene WTS (TNMWF) currently stands at 1000.0 days. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 99899%. Across the settlements charted above, it has ranged from 1.0 to 1000.0 days.

TNMWF Company Profile & Sector Positioning

TNL Mediagene WTS (TNMWF) and is listed on the OTC.

Investors comparing TNMWF often look at related companies in the same sector, including Brookfield Corp A 24 (BAMGF), Fortis Inc PFD F (FORFF), TransAlta Corp PFD E (TSLTF), DBV Technologies SA (DBVTF), and Sunrise Communications A (SNNRF). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate TNMWF's relative position within its industry.

Frequently Asked Questions

TNL Mediagene WTS (TNMWF) has no recent trading. Its last close was $0.0013 on November 11, 2026.

The FY2025 revenue of TNL Mediagene WTS (TNMWF) is $45.0M, from its most recent completed fiscal year.

The FY2025 net income of TNL Mediagene WTS (TNMWF) is -$44.6M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of TNL Mediagene WTS (TNMWF) is -$25.91 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of TNL Mediagene WTS (TNMWF) is -$4.9M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of TNL Mediagene WTS (TNMWF) is -99.0% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The gross profit margin of TNL Mediagene WTS (TNMWF) is 31.1% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of TNL Mediagene WTS (TNMWF), current assets divided by current liabilities, was 0.50 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of TNL Mediagene WTS (TNMWF) is $14.0M for FY2025, its most recent completed fiscal year.

The operating income of TNL Mediagene WTS (TNMWF) is -$49.6M for FY2025, its most recent completed fiscal year. Learn about operating income.

TNL Mediagene WTS (TNMWF) is a warrant security linked to the ordinary shares of TNL Mediagene, a foreign private issuer that reports to the U.S. Securities and Exchange Commission. Its value is tied to the underlying equity of TNL Mediagene.

TNL Mediagene is identified in its SEC filings as a foreign private issuer that files annual reports on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934.

Form 20-F annual reports and Form 6-K current reports for TNL Mediagene are most relevant. These filings describe the company’s status, material agreements and corporate communications that can affect the underlying shares and related warrants.

TNL Mediagene describes an ordinary share purchase agreement with Tumim Stone Capital LLC, referred to as an equity line of credit. An amendment to this agreement revises how Tumim’s purchases of TNL Mediagene’s ordinary shares are valued, including the choice of a one- or three-day pricing valuation period and related purchase terms.

According to a Form 6-K, TNL Mediagene and Tumim Stone Capital LLC entered into a third amendment to the ordinary share purchase agreement. The amendment allows TNL Mediagene to select a one- or three-trading-day pricing valuation period based on market price and/or volume, with corresponding adjustments to the maximum purchase amount and purchase price.

TNL Mediagene’s Form 6-K filings list exhibits such as press releases, shareholder letters and the full text of amendments to the ordinary share purchase agreement with Tumim Stone Capital LLC. These exhibits provide additional detail beyond the summaries in the filings.

In its Form 6-K filings, TNL Mediagene lists locations in Tokyo, Japan and Taipei City, Taiwan as part of its corporate information.